- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Helen Burstin Describes NQF's Role in the Core Quality Measures Collaborative
Helen Burstin, MD, MPH, FACP, chief scientific officer of The National Quality Forum, said that quality measurement is at the core of transitioning to value-based payment, and that the initiative can’t truly move forward without putting the work in to identify and define what that value is.
Helen Burstin, MD, MPH, FACP, chief scientific officer of The National Quality Forum, said that quality measurement is at the core of transitioning to value-based payment, and that the initiative can’t truly move forward without putting the work in to identify and define what that value is.
Transcript (slightly modified)
What is the National Quality Forum’s involvement in the Core Quality Measures Collaborative?
NQF’s been engaged in the CMS AHIP measures collaborative from the very beginning, actually, and have played several important roles. I think one of which is to be a technical advisor as the different work groups are focused on a particular content area. We could bring forward all the endorsed measures in that space. We could point to particular measures that maybe they wouldn’t have thought of otherwise but we’ve really been engaged as part of those efforts.
And then lastly, we’ve also been engaged in ensuring that the collaborative had a broader set of stakeholders at the table as it moved beyond the initial plan, the physician groups and now to a broader set of stakeholders.
What is the role of quality measurement in the move toward value-based care?
It is clear that measurement is core towards making that transition to value-based payment. We can’t move forward with doing work based on really identifiying the value, which is combination of cost and outcomes in particular, unless you’ve got those outcomes ready to go. So we really see measurement as being core to that shift to value-based purchasing.
And in fact, if we perform well in outcomes, our hope would be, we would ultimately reduce costs and really get a better value. That being said, there are a fair number of measurement gaps. Gaps in terms of the outcomes where they are, so one of our visions is to try to be out there, finding out where the best possible measures are, harvesting for those, bringing them forward and trying to get them used as part of these national efforts.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Strategies for Improving Patient Access to Dermatology Care
March 22nd 2025Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
